The United States Food and Drug Administration (USFDA) has inspected the Unit I, a Formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, situated at Koltur Village, Shameerpet, Medchal District, Telangana, from July 17, 2023 to July 26, 2023. The inspection closed with zero observations and a classification of No Action Indicated (NAI).
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
